Annual Total Long Term Liabilities
$145.60 M
+$9.50 M+6.98%
31 December 2023
Summary:
Aquestive Therapeutics annual total long term liabilities is currently $145.60 million, with the most recent change of +$9.50 million (+6.98%) on 31 December 2023. During the last 3 years, it has risen by +$23.43 million (+19.18%). AQST annual total long term liabilities is now at all-time high.AQST Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$140.23 M
+$1.04 M+0.75%
30 September 2024
Summary:
Aquestive Therapeutics quarterly total long term liabilities is currently $140.23 million, with the most recent change of +$1.04 million (+0.75%) on 30 September 2024. Over the past year, it has dropped by -$5.37 million (-3.69%). AQST quarterly long term liabilities is now -5.10% below its all-time high of $147.77 million, reached on 31 March 2024.AQST Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AQST Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -3.7% |
| 3 y3 years | +19.2% | +14.8% |
| 5 y5 years | +120.5% | +112.3% |
AQST Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +19.2% | -5.1% | +14.8% |
| 5 y | 5 years | at high | +120.5% | -5.1% | +112.3% |
| alltime | all time | at high | +232.3% | -5.1% | +220.0% |
Aquestive Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $140.23 M(+0.7%) |
| June 2024 | - | $139.19 M(-5.8%) |
| Mar 2024 | - | $147.77 M(+1.5%) |
| Dec 2023 | $145.60 M(+7.0%) | $145.60 M(+5.3%) |
| Sept 2023 | - | $138.32 M(+10.7%) |
| June 2023 | - | $124.99 M(-4.0%) |
| Mar 2023 | - | $130.14 M(-4.4%) |
| Dec 2022 | $136.10 M(+11.4%) | $136.10 M(+10.6%) |
| Sept 2022 | - | $123.10 M(+0.1%) |
| June 2022 | - | $123.03 M(-2.0%) |
| Mar 2022 | - | $125.49 M(+2.7%) |
| Dec 2021 | $122.16 M | $122.16 M(+21.4%) |
| Sept 2021 | - | $100.60 M(+3.1%) |
| June 2021 | - | $97.61 M(+4.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2021 | - | $93.67 M(+3.8%) |
| Dec 2020 | $90.28 M(+36.7%) | $90.28 M(+31.7%) |
| Sept 2020 | - | $68.57 M(-2.1%) |
| June 2020 | - | $70.05 M(+0.1%) |
| Mar 2020 | - | $69.95 M(+5.9%) |
| Dec 2019 | $66.05 M(+50.7%) | $66.05 M(+4.5%) |
| Sept 2019 | - | $63.22 M(+25.4%) |
| June 2019 | - | $50.44 M(+13.6%) |
| Mar 2019 | - | $44.40 M(+1.3%) |
| Dec 2018 | $43.82 M(-19.2%) | $43.82 M(-3.1%) |
| Sept 2018 | - | $45.24 M(-18.2%) |
| June 2018 | - | $55.31 M(+21.8%) |
| Mar 2018 | - | $45.43 M(-16.3%) |
| Dec 2017 | $54.26 M(+17.6%) | $54.26 M |
| Dec 2016 | $46.16 M | - |
FAQ
- What is Aquestive Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Aquestive Therapeutics?
- What is Aquestive Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Aquestive Therapeutics?
- What is Aquestive Therapeutics quarterly long term liabilities year-on-year change?
What is Aquestive Therapeutics annual total long term liabilities?
The current annual total long term liabilities of AQST is $145.60 M
What is the all time high annual total long term liabilities for Aquestive Therapeutics?
Aquestive Therapeutics all-time high annual total long term liabilities is $145.60 M
What is Aquestive Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of AQST is $140.23 M
What is the all time high quarterly long term liabilities for Aquestive Therapeutics?
Aquestive Therapeutics all-time high quarterly total long term liabilities is $147.77 M
What is Aquestive Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, AQST quarterly total long term liabilities has changed by -$5.37 M (-3.69%)